Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells

Molecular Immunology

Volumn 70, Issue , 2016, Pages 13-23

  Lindorfer, Margaret A ^a   Cook, Erika M ^a   Tupitza, Jillian C ^a   Zent, Clive S ^b   Burack, Richard ^b   de Jong, Rob N ^c   Beurskens, Frank J ^c   Schuurman, Janine ^c   Parren, Paul W H I ^c   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c GENMAB   (Netherlands)

Author keywords

Complement dependent cytotoxicity; Immunotherapy; Real time movies

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C9; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7D8; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; B-CELL LEUKEMIA CELL LINE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER IMMUNOTHERAPY; CELL DEATH; CELL KILLING; CELL VIABILITY; CHEMICAL MODIFICATION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIGITAL IMAGING; FLOW CYTOMETRY; HEXAMERIZATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; WILD TYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL LINE; IMMUNOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROSCOPY, CONFOCAL; RITUXIMAB;

EID: 84949633856     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.12.007     Document Type: Article

References (49)

1. Baig N.A., Taylor R.P., Lindorfer M.A., Church A.K., LaPlant B.R., Pavey E.S., Nowakowski G.S., Zent C.S. Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement. Leuk. Lymphoma 2012, 53:2218-2227.
2. Baig N.A., Taylor R.P., Lindorfer M.A., Church A.K., LaPlant B.R., Pettinger A.M., Shanafelt T.D., Nowakowski G.S., Zent C.S. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J. Immunol. 2014, 192:1620-1629.
3. Berger H.J., Taratuska A., Smith T.W., Halperin J.A. Activated complement directly modifies the performance of isolated heart muscle cells from guinea pig and rat. Heart Circ. Physiol. 1993, 34:H267-H272.
4. 2+ influx and induces streamers. Eur. J. Immunol. 2011, 41:2436-2446.
5. Beurskens F.J., Lindorfer M.A., Farooqui M., Beum P.V., Engelberts P., Mackus W.J.M., Parren P.W.H.I., Wiestner A., Taylor R.P. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 2012, 188:3532-3541.
6. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
7. Campbell A.K., Daw R.A., Hallett M.B., Luzio J.P. Direct measurement of the increase in intracellular free calcium ion concentration in response to the action of complement. Biochem. J. 1981, 194:551-560.
8. 2+. J. Immunol. 1986, 137:263-270.
9. Cole D.S., Morgan B.P. Beyond lysis: how complement influences cell fate. Clin. Sci. 2003, 104:455-466.
10. Diebolder C.A., Beurskens F.J., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J.R., van de Winkel J.G.J., Wilson I.A., Koster A.J., Taylor R.P., Saphire E.O., Burton D.R., Schuurman J., Gros P., Parren P.W.H.I. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260.
11. DiLillo D.J., Pawluczkowycz A.W., Peng W., Kennedy A.D., Beum P.V., Lindorfer M.A., Taylor R.P. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol. Immunol. 2006, 43:1010-1019.
12. Fishelson Z., Donin N., Zell S., Schultz S., Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 2003, 40:109-123.
13. Golay J., Zaffaroni L., Vaccari T., Lazari M., Borleri G., Bernasconi S., Tedesco F., Rambaldi A., Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 2000, 95:3900-3908.
14. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., Kirschfink M. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 1999, 36:929-939.
15. Kanaji S., Iwahashi J., Kida Y., Sakaguchi M., Mihara K. Characterization of the signal that directs Tom20 to the mitochondrial outer membrane. J. Cell Biol. 2000, 151:277-288.
16. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., Densmore J.J., Williams M.E., Taylor R.P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 2004, 172:3280-3288.
17. Kennedy A.D., Solga M.D., Schuman T.A., Chi A.W., Lindorfer M.A., Sutherland W.M., Foley P.L., Taylor R.P. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab. Blood 2003, 101:1071-1079.
18. Koski C., Ramm L., Hammer C., Mayer M., Shin M. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:3816-3820.
19. Lemasters J.J., Theruvath T.P., Zhong Z., Nieminen A.L. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta 2009, 1787:1395-1401.
20. Li B., Zhao L., Guo H., Wang C., Zhang X., Wu L., Chen L.T.Q., Qian W., Wang H., Guo Y. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009, 114:5007-5015.
21. Melis J.P.M., Strumane K., Ruuls S.R., Beurskens F.J., Schuurman J., Parren P.W.H.I. Complement in therapy and disease regulating the complement system with antibody-based therapeutics. Mol. Immunol. 2015, 67:117-130.
22. 2+ pump inhibitors. Biochem. Soc. Trans. 2011, 39:789-797.
23. Mollnes T.E., Lea T., Harboe M., Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand. J. Immunol. 1985, 22:183-195.
24. Morgan B.P. Effects of the membrane attack complex of complement on nucleated cells. Curr. Topic. Microbiol. Immunol. 1992, 178:115-140.
25. Morgan B.P., Imagawa D.K., Dankert J.R., Ramm L.E. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis. J. Immunol. 1986, 136:3402-3406.
26. 2+ in complement membrane attack. Cell Calcium 1986, 7:399-411.
27. Ollert M.W., Kadlec J.V., David K., Petrella E.C., Bredehorst R., Vogel C.W. Antibody-mediated complement activation on nucleated cells: a quantitative analysis of the individual reaction steps. J. Immunol. 1994, 153:2213-2221.
28. 2+ pumps: invention and applications of caloxins. World J. Biol. Chem. 2011, 2:39-47.
29. 2+ deregulation on mitochondrial membrane potential and cell viability in nucleated cells following lytic complement attack. Cell Calcium 1994, 15:217-227.
30. Papadimitriou J.C., Ramm L.E., Drachenberg C.B., Trump B.F., Shin M.L. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J. Immunol. 1991, 147:212-217.
31. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., Lindorfer M.A., van de Winkel J.G.J., Parren P.W.H.I., Taylor R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 2009, 183:749-758.
32. 2+-dependent apoptosis through the mitochondrial pathway. J. Biol. Chem. 2004, 279:25219-25225.
33. Pokrass M.J., Liu M.F., Lindorfer M.A., Taylor R.P. Activation of complement by monoclonal antibodies that target cell-associated β2-microglobulin: implications for cancer immunotherapy. Mol. Immunol. 2013, 56:549-560.
34. Qian T., Herman B., Lemasters J.J. The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol. Appl. Pharmacol. 1999, 154:117-125.
35. Reiter Y., Ciobotariu A., Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur. J. Immunol. 1992, 22:1207-1213.
36. Reiter Y., Ciobotariu A., Jones J., Morgan B.P., Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J. Immunol. 1995, 155:2203-2210.
37. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013, 190:3831-3838.
38. Rus H.G., Niculescu F.I., Shin M.L. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol. Rev. 2001, 180:49-55.
39. 2+ and ATP Permeability thresholds in live cells attacked by complement. Immunology 1998, 93:601-609.
40. Schanne F.A.X., Kane A.B., Young E.E., Farber J.L. Calcium dependence of toxic cell death: a final common pathway. Science 1979, 206:700-702.
41. Shirazi Y., McMorris F.A., Shin M.L. Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyteXC6 glioma cell hybrids. J. Immunol. 1989, 142:4385-4391.
42. Taylor R.P., Lindorfer M.A. The role of complement in mAb-based therapies of cancer. Methods 2014, 65:18-27.
43. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 2004, 104:1793-1800.
44. Teeling J.L., Mackus W.J.M., Wiegman L.J.J.M., van den Brakel J.H.N., Bees S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., Parren P.W.H.I., Glennie M.J., van de Winkel J.G.J. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177:362-371.
45. 2+ fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 2013, 126:2903-2913.
46. van Meerten T., rosemuller H., Hol S., Moerer P., Zwart M., Hagenbeek A., Mackus W.J.M., Parren P.W.H.I., van de Winkel J.G.J., Ebeling S.B., Martens A.C. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20, can effectively eliminate CD20low expressing tumor cells that resist Rituximab mediated lysis. Haematologica 2010, 95:2063-2071.
47. Walport M.J. Complement. N. Engl. J. Med. 2001, 344:1058-1066.
48. Walshe C.A., Beers S.A., French R.R., Chan C.H.T., Johnson P.W., Packham G.K., Glennie M.J., Cragg M.S. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J. Biol. Chem. 2008, 283:16971-16984.
49. Zong W.X., Thompson C.B. Necrotic death as a cell fate. Genes Dev. 2006, 20:1-15.